Zibb.com: Nektar Therapeutics (Industry News & Blogs)

Nektar Therapeutics Q3 net loss decreases - Zibb.com

Fri, 06 Nov 2009 05:02:21 GMT

Nektar Therapeutics, a US-based biopharmaceutical company, has reported a net loss of $30.97 million or $0.33 per share, for the third quarter ended September 30, 2009, compared to $37.04 million or $0.40 per share, for the third quarter ended September 30, 2008. Total revenues were $10.22 million

Nektar Therapeutics Reports Third Quarter 2009 Financial Results ...

Wed, 04 Nov 2009 21:15:00 GMT

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR - News) today reported its financial results for the third quarter ended September 30, 2009.Net

Nektar Therapeutics up 15%

Mon, 21 Sep 2009 13:46:23 GMT

NKTR Stock Quote, and financial news from the leading provider and award-winning MarketWatch.com.

Nektar Therapeutics Signs Licensing Deal with AstraZeneca PLC for...

Mon, 21 Sep 2009 12:00:00 GMT

Both programmes were developed by Nektar, utilizing their proprietary small molecule advanced polymer conjugate technology platform.

Nektar Therapeutics to Present at the UBS 2009 Global Life Scienc...

Fri, 18 Sep 2009 19:07:00 GMT

SAN CARLOS, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2009 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 22, 2009 at 10:30 a.m. Eastern time.

Nektar Therapeutics initiated with "outperform"

Fri, 11 Sep 2009 16:18:52 GMT

NEW YORK, September 11 (newratings.com) - Analysts at Boenning & Scattergood initiate coverage of Nektar Therapeutics (ticker: NKTR) with an "outperform" rating. The target price is set to $11. [more]

Nektar Therapeutics reports $32M loss in Q2 (at bizjournals.com)

Wed, 05 Aug 2009 13:05:16 GMT

Drug business Nektar Therapeutics Inc. lost $32.1 million in the second quarter, compared with a loss of $33.4 million in the same quarter a year earlier. San Carlos-based Nektar (NASDAQ: NKTR) had revenue of $13 million in the June quarter, down from revenue of $20.

Nektar Therapeutics narrows Q2 loss to $32.1M (at bizjournals.com...

Wed, 05 Aug 2009 12:05:14 GMT

Nektar Therapeutics Inc. reported a slightly narrowed second quarter loss of $32.1 million, or 35 cents a share, compared to a loss of $33.4 million, or 36 cents a share in the same period last year.

Nektar Therapeutics Q3 2008 Earnings Call Transcript (at Seeking ...

Thu, 20 Nov 2008 09:37:10 GMT

Good afternoon and thank you for joining us for the Nektar Therapeutics conference call. My name is Madge [ph], and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be conducting a question-and-answer session toward the end of this conference.

Nektar Therapeutics Repurchases $100 Million of Convertible Debt ...

Thu, 06 Nov 2008 21:41:00 GMT

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results. - SAN CARLOS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR - News) today announced that it has repurchased 32%, or $100.0 million, of its outstanding

Nektar Therapeutics to Webcast R&D Day on November 12th (PR Newsw...

Mon, 27 Oct 2008 12:30:00 GMT

Nektar Therapeutics to Webcast R&D Day on November 12th. - SAN CARLOS, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR - News) announced that it will host an R&D Day for investors and analysts at the InterContinental Hotel in New York on Wednesday, November 12, 2008,

Novartis to Buy Nektar's Pulmonary Business (at TheStreet.com)

Tue, 21 Oct 2008 09:34:57 GMT

The Swiss drug maker will acquire the assets for $115 million in cash.. Check out TheStreet for the latest stock market news and financial investment headlines.

Nektar Therapeutics' President and CEO, Howard W. Robin, to Prese...

Tue, 16 Sep 2008 21:43:00 GMT

m. ET. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2008.

5 More Unloved Growth Stocks (at Motley Fool)

Mon, 19 May 2008 17:29:00 GMT

We rebel investors at Motley Fool Rule Breakers believe the multibaggers in the making, while not often cheap by the numbers, are always misunderstood. The extraordinary skepticism they face makes them excellent value stocks.

Guru Stocks at 52-Week Low: The Clorox Company, Avnet Inc, Lincar...

Sun, 20 Apr 2008 03:22:30 GMT

GuruFocus tracks the stock buys, sells and commentaries of stock investment gurus such as Warren Buffett, George Soros, the best investors.

MannKind and Nektar React to New Exubera Data

Wed, 16 Apr 2008 04:00:00 GMT

MannKind suspended discussions with potential partners for the commercialization of its "Technosphere Insulin" product.

Pfizer, Nektar Warn of Cancer After Insulin Powder

Wed, 09 Apr 2008 21:44:00 GMT

Pfizer Inc. reported an increase of lung cancer among patients who used its discontinued inhaled insulin Exubera, another setback for developers of needle-free diabetes treatments. Shares of MannKind Corp.

Lilly Ends Effort to Develop an Inhaled Insulin Product

Sat, 08 Mar 2008 07:09:22 GMT

The company’s decision is the third setback in recent months for such insulin formulations, once deemed potential blockbuster products because of their greater convenience.

Novo axes inhaled insulin drug trial (at FT.com)

Wed, 16 Jan 2008 02:30:13 GMT

Novo Nordisk, the Danish pharmaceuticals group, on Tuesday announced a DKr1.3bn charge as it became the second significant drug company to abandon plans for an inhaled version of insulin for diabetics.

Pfizer to Discontinue Sales of Inhaled Insulin Drug Exubera

Sat, 20 Oct 2007 02:47:28 GMT

Pfizer announced on Thursday its decision to discontinuesales of its new inhaled insulin drug Exubera. Exubera was developed by San Carlos-based Nektar Therapeutics, which licensed the drug to Pfizer. According to the

FDA Lets Scientists With Drug Company Ties Evaluate New Insulin P...

Fri, 09 Sep 2005 00:00:00 GMT

The Food and Drug Administration (FDA) is under fire again today for allowing scientists with direct financial ties to a drug manufacturer to serve on an advisory committee charged with evaluating that company's product...

Shares of Nektar Therapeutics up 10% on clinical results-16/06/20...

Mon, 16 Jun 2003 21:03:23 GMT

HOUSTON (CNI)--Shares of drug discovery firm Nektar Therapeutics rose 10% or $1.

Nektar Therapeutics News - The New York Times

The discontinuation of Exubera, an inhaled insulin, is another black eye for Pfizer, the world’s biggest drug company, which has recently sustained a series of reversals.

NPS Pharmaceuticals | News | Press Releases

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) and Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that they have signed a definitive agreement to a merger of equals in a stock-for-stock transaction with a value of approximately $1.6 billion.

SAN CARLOS, Calif., Dec 31, 2008 /PRNewswire-FirstCall via COMTEX...

SAN CARLOS, Calif., Dec 31, 2008 /PRNewswire-FirstCall via COMTEX/ -- Nektar Therapeutics (NASDAQ GS:NKTR) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash.